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Abstract 
During menopause, many women are prescribed hormone replacement therapy (HRT) to alleviate 
disruptive symptoms.  Many assume that herbal HRTs are safer than prescription HRTs because they are 
“natural”, even though they are not regulated in either composition or dose by the FDA. Promensil is one 
of these supplements.  The proliferative effects of its specific components, biochanin A and formononetin 
were investigated using human ductal carcinoma cells. Results indicate that cell proliferation is inhibited 
by high concentrations of biochanin A (>10µM) and promoted at low concentrations (<10µM), while 
formononetin had no effect on cell proliferation.  These results indicate that herbal HRTs may not be safe 
for women with breast cancer. 
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Introduction 
Menopause is a normal bodily process that women go through in which menstruation and fertility 
come to an end. In the United States, the average age for women to go into menopause is about 51 years.  
As a woman ages there is a natural decline in the level of reproductive hormones in her body. More 
specifically, the levels of estrogen and progesterone decline during menopause. Menopause is associated 
with uncomfortable symptoms in addition to the decrease in menstruation and fertility. These symptoms 
include hot flashes, mood swings, sleep disturbances, and increased abdominal fat among others. To 
lessen and sometimes alleviate the symptoms of menopause there are several treatments, Hormone 
Replacement Therapy (HRT) being the most commonly known and effective of these (1).  This therapy 
entails replacing the hormones the body no longer produces. Initially it was believed that there were long-
term benefits to using HRT in addition to just reducing symptoms, including fewer incidences of 
osteoporosis and heart disease. However, longer term studies revealed that some of the more prevalent 
negative side effects of HRT were an increased risk of breast cancer, stroke, blood clots, and 
mammogram abnormalities (2).  
Incidences of these negative side effects caused many doctors to not prescribe HRT as a 
treatment. In an effort to find relief, women began to turn to herbal supplements that were believed to be 
more natural. Herbal supplements contain phytoestrogens as a means of treating the symptoms of 
menopause, though there have been few studies that have provided conclusive evidence that these 
alternatives are any safer (1). Because phytoestrogens may mimic estrogens they could potentially cause 
hormone imbalances and lead to cancer.  
Obtaining more of an understanding as to how phytoestrogens affect the human body is 
instrumental in providing women with the information needed to make healthy decisions. Some research 
has been done, but not enough to create a clear understanding of the effects of phytoestrogens. Some 
sources claim that phytoestrogens are able to induce the development of breast cancer; one of the major 
concerns associated with classic HRT (3). Other studies have suggested that there are anticancer effects of 
a diet rich in phytoestrogens (4). This divide in the understanding of how phytoestrogens actually affect 
the body is very evident.  In order for women to make an educated and appropriate decision as to how to 
treat their menopause symptoms, there first need to be reliable data on which to base these decisions.  
In an effort to close the gap of understanding about phytoestrogens, the primary hormones found 
in the popular supplement Promensil, biochanin A and formononetin, were tested on human breast cancer 
cells. These particular hormones are common to red clover, which is used in several herbal hormone 
replacement therapies (5). A major concern about these hormones is that they will have the same negative 
effects that are associated with classic HRT. By testing the phytoestrogens on human breast cancer cells, 
their potential to cause increased proliferation of breast cancer can be assessed. This will provide a 
baseline and direction in which further research can be conducted.  
 
  
Background  
Menopause 
Menopause is currently defined as the cessation of the menstrual cycle for a twelve month period 
(6).  During this time, many chemical and physiological changes occur such as a decrease in endogenous 
estrogens.  It has been found that women in menopause over the age of 60 have much less endogenous 
androstenedione, testosterone, estrone, and estradiol than women under the age of 40 still having their 
periods. Though these declines occur, stability of clearance and metabolism rates remain relatively stable 
(6).  Also, the main form of estrogen in the body switches from estradiol to estrone (7).  Physiologically, 
follicles within the ovary also decrease with age.  At menopause, the ovary can become fibrotic, 
hyperplastic, or hypertrophic.  Women with hypertrophic ovaries may still produce significant amounts of 
androstenedione and testosterone for years, therefore every woman experiences menopause differently 
(6).  
 Many women experience physiological changes including mood swings, drying of the mucous 
membranes, behavioral changes, sleep disturbances, bone loss, and a myriad of other issues (7). The most 
common side effects that women seek treatment for are hot flashes (8).  This symptom is important to this 
study because the most commonly prescribed and effective form of drug treatment for this symptom is 
hormone replacement therapy.  Hot flashes are characterized by heat, flushing, sweating, anxiety, and 
chills.  This occurs most frequently in the first two years of menopause, but can last for much longer (7).    
Few conclusions have been drawn by the scientific community as to the cause of hot flashes.  
Low levels of estrogen have been implicated, but prepubescent girls with low levels of estrogen do not 
have hot flashes.  Luteinizing hormone and gonadatrophin releasing hormones also have shown little 
correlation.  Some postulate, however, that it is estrogen withdrawal that causes these uncomfortable 
symptoms. Circulating levels of estrone and estradiol are lower in postmenopausal women with hot 
flashes than in women with normal hormone levels.  Also, women with gonadal dysgenesis who have 
never had normal levels of estrogen do not experience hot flashes unless they are first exposed to, and 
then withdrawn from estrogen.  Hormone replacement therapy, therefore, would be effective in abating 
the symptoms of estrogen withdrawal (8). 
Hormone Replacement Therapy 
Hormone replacement therapy was first popularized in 1966 by Robert A. Wilson, M.D. in a book 
called Feminine Forever, which advocated "estrogen replacement treatment".  This school of thought 
believed that by replacing endogenous estrogen lost during menopause, women could avoid all or at least 
some of the symptoms.  Women undergoing hormone replacement have reported a reduction in hot 
flashes, mood swings, osteoporosis, urogenital atrophy, atherosclerotic cardiovascular disease, lower 
blood pressure, lower cholesterol, and lower angina and myocardial infarction (7).   
Prescription vs. Nonprescription 
There are two main types of hormone replacement therapy: prescription and nonprescription.  
Even within these groups, hormone replacement therapies vary in types, formulations, doses, and routes 
of administration.  A company seeking FDA approval for a prescription drug must conduct testing and 
provide information on its drug’s efficacy and safety.  The FDA does not conduct testing itself, but 
provides certified physicians, statisticians, chemists, pharmacologists, and other professionals who review 
the company’s data.   If this group determines that the drug’s health benefits are greater than its known 
risks, the drug receives approval (9).  In this way, the FDA does not ensure that no adverse effects can 
occur, but it does serve as a form of control.   
In contrast, nonprescription, or over the counter drugs, are not as heavily regulated.  These drugs 
only require a drug monograph, described by the FDA as a “recipe book covering acceptable ingredients, 
doses, formulations, labeling, and testing parameters”.  Products that conform to a monograph can be 
marketed without FDA pre-approval, taking out an important normalizing step (9). 
Links to Breast Cancer 
Though hormone replacement therapies have been shown to effectively mitigate the symptoms of 
menopause, there have been concerns over their long term safety.  As early as 1975, reports were 
published in the New England Journal of Medicine linking exogenous estrogens to endometrial cancer 
(7).   
Much of the concern over hormone replacement therapy surrounds the ability of estrogens to bind 
to estrogen receptors.  According to Dip et. al., in the normal mammary gland, estrogen receptors are 
expressed in a small number of epithelial cells that are most non-dividing (10).   In a majority of breast 
cancers (~70%), estrogen receptors are up regulated, and the tumor becomes estrogen responsive (11) 
(12) (13).     
 There are two major subtypes of the estrogen receptor: alpha (α) and beta (β).  The estrogen 
receptor is part of the steroid/retinoid receptor gene super family, and is a soluble DNA-binding protein 
that acts as ligand-activated enhancer factor.  When the receptor binds to an estrogenic compound, it 
activates transcription by then binding to palindromic sequences called estrogen-responsive elements in 
the promoters of target genes.  In this way the receptor up regulates gene expression (14) (15).  There can 
be dissimilar effects when different conformations of receptor ligand binding occur, making investigation 
of each hormone very important.  Though the estrogen receptor is an important factor in cell responses to 
hormones, estrogens can act upon the cell in independent pathways.  Estrogens have been shown to 
regulate cell-signaling pathways, reduce proliferation, and induce apoptosis in cells lines without estrogen 
receptors (16). 
Many researchers have attempted to verify if hormone replacement therapy can cause or affect 
cancer growth, however, human studies are often plagued by conflicting results, and questions arise 
regarding the appropriateness of control groups, validity of exposure information, and role of selection 
biases. Also the ovarian status, duration of hormone use, intervals of use, subject subgroups and 
interactions with other breast cancer risk factors confound trials.  Some risk factors are long term use 
(greater than 10 years), higher doses, and late-age menopause (17).  Yet, over and over, people are unable 
to conduct medical reviews that show conclusively if hormone replacement therapy can cause breast 
cancer, or protect against it (18) (19) (20) (21).   
In the past decade, much data has surfaced pointing to the potentially harmful effects of hormone 
replacement therapy.  A serious backlash against HRTs was created in 2003 by a study by the Women’s 
Health Initiative on the effects of HRT containing estrogen and progestin on healthy women.  This study 
was abruptly stopped because the risk of the trial was greater than the proposed health benefits (22).   In 
an attempt to avoid the risks associated with traditional hormone replacement, many women began to 
search for alternative therapies.    
 
Phytoestrogens 
Phytoestrogens are plant hormones that have similar structure and function as mammalian 
estrogens.  Shown below in Figure 1 are the two main forms of estrogen in the human body, estradiol and 
estrone, and the two phytoestrogens investigated in this project. 
 
 
  
Estradiol      Estrone 
  
 
 
 
Biochanin A      Formononetin 
Figure 1: Structure of mammalian estrogens and plant phytoestrogens 
 
 As can be seen in Figure 2, these hormones share very similar structures.  Red lines denote 
common molecular bonds.  The two phenol groups denoted by “P” are the proposed reason for the ability 
of phytoestrogens to bind to estrogen receptors in the human body (16).  Other sources propose that only 
one aromatic ring and a hydroxyl group are necessary for effective binding of the estrogen receptor 
because the rest of the receptor will allow hydrophobic groups (22).  Other important factors are the 
spacing between the hydrophobic and hydrogen bond interactions, the degree and size of the alkyl group, 
and its location on the phenolic ring.    
 
Figure 2: Structural similarities between mammalian estrogens and plant phytoestrogens 
 
As they are so similar, phytoestrogens have been discussed as agonists and antagonists of the 
estrogen receptor depending on the tissue, concentration, and how much endogenous estrogen is already 
present.  Because of this, they are sometimes called selective estrogen receptor modulators, or SERMS 
(22).   The structural similarities to endogenous estrogens and the ability to act as SERMS have led 
people to believe that phytoestrogens may provide relief from menopause symptoms without the potential 
dangerous side effects. 
A major drawback to phytoestrogens, however, is their variability.  Most phytoestrogens are 
marketed as extracts contained in nonprescription medications.  This nonprescription status allows 
companies great leeway in determining the components of their product.   Formulations, dosages, and 
delivery methods vary between brands, and even between lots of the same product.  Though many 
companies may attest to following their monograph, scientists have found high variability in even some 
of their most basic components.  In one study, red clover products such as Promensil were analyzed for 
hormone content, and how the carrier matrix of the product affected its intestinal deposition.  The authors 
found that isoflavone content varied significantly between products, in addition to the hormone absorption 
rates.  Two of the hormones most greatly affected by the matrix were biochanin A and formononetin.  The 
rates of absorption, metabolism, permeability, and excretion were highly variable and greatly affected by 
the carrier matrix (23).  This is alarming as women who decide to use hormonal therapies may be 
receiving more or less of their “prescribed” dosage with little knowledge of the actual safety and efficacy 
of the product which she has chosen. 
 The two phytoestrogens studied in this project were biochanin A and formononetin.  Both of 
these are considered isoflavones, and are commonly found in hormone replacement therapies derived 
from red clover (Trifolium pretense).  When ingested, biochanin A can be metabolized into genistein, and 
formononetin into daidzein.  Figure 3 illustrates the metabolic changes that these hormones undergo.  It 
has been noted that the metabolites of these first two hormones may not have the same effect as their 
precursors (22).    
 
Figure 3: Metabolism of biochanin A and formononetin with structural images of each molecule 
 
Biochanin A 
Overall, biochanin A has been found to induce breast cancer cell proliferation at concentrations 
lower than 10µM and cause inhibition at concentrations greater than 20µM. It has also been found that an 
estrogen responsive MCF7 cell line proliferated in response to biochanin at concentrations less than 
0.1uM, mediated through the estrogen receptor (24).   Another study using an estrogen responsive MCF7 
line showed that cell proliferation was inhibited at an IC50 value of 20µM (25). Taken together with other 
studies (26) (3) (27), these results suggest that concentrations lower than 0.1µM will cause proliferation, 
possibly including up to 10µM, but concentrations higher than 20µM may have inhibitory effects through 
estrogen receptor independent means. 
 
Formononetin 
The other hormone investigated in this project was found to be a proliferation inducing agent at all 
concentrations in a dose dependent manner.  One study found that formononetin has estrogenic activity in 
a concentration dependent manner from 0.5 to 500uM on an estrogen responsive MCF7 line.  Inhibition 
by a known estrogen antagonist at 100nM pointed to great similarity to endogenous estrogen (28).  
Another study also found that formononetin binds both the alpha and beta forms of the estrogen receptor 
and induces cell proliferation and gene expression in breast cancer and endometrial cells in an estrogen 
receptor dependent manner.  A known estrogen antagonist was also found to inhibit formononetin 
induced proliferation of estrogen receptor positive breast cancers (29).  
 The same types of results were found in a live model investigating rat mammary gland 
proliferation.  Estrogenic effects were found in rats given formononetin at 40mg/kg subcutaneously.  This 
study found mammary gland proliferation was enhanced 3.3 fold over saline treated controls when 
animals were treated with formononetin.  Estrogen receptor expression in animals given formononetin 
was twofold higher than control, even though formononetin was found to have a binding affinity 15,000 
times less than that of 17β-estradiol.  The authors concluded that formononetin supports mammary gland 
proliferation, but estrogenic potency is extremely weak compared with 17β-estradiol (25).  These results 
suggest that formononetin will increase estrogen responsive cancer cell proliferation in a dose dependent 
manner through the estrogen receptor. 
 
  
Methods 
Media 
 Different media compositions were used for different stages of the experiment. For cell 
maintenance of the T47D cell line the base media was Roswell Park Memorial Institute Media (RPMI), 
10% Fetal Bovine Serum (FBS) and 2mg/ml insulin. 
 The media used during the Promega Cell Titer 96 AQ Non-radioactive Proliferation Assay One 
Step assay contained altered RPMI and FBS. Due to estrogenic effects associated with phenol red, 
experiments were conducted in phenol red free RPMI. Charcoal stripped serum was used in these 
experiments in an effort to reduce the steroid levels from the serum that could cause false positive and 
other incorrect findings. 
Cells 
 The cell line used in the experiments was T47D. It was derived from a human epithelial breast 
duct carcinoma that was isolated and cataloged with the ATCC. These cells were initially plated from a 
frozen stock in a T25 flask to prepare for expansion and splitting.  The cells were maintained about three 
times a week with fresh media and passaging, as needed. The cells were incubated at 37°C and 5% CO2. 
Some of the cells were frozen down as a stock for future use.   
Reagents 
 50 mg insulin derived from bovine pancreas was dissolved in 200ml of 18N glacial acetic acid 
and 10ml of distilled water. This provided a 2mg/ml concentration to work with. 17β – Estradiol (>98% 
pure), formononetin (> 99% pure), and biochanin A were dissolved in dimethyl sulfoxide (DMSO) to 
create stock solutions of 0.10M. With this stock solution the needed concentrations for testing the 
hormones was achieved via serial dilution.   
Assays 
 The Promega Cell Titer 96 AQ Non-radioactive Proliferation Assay One Step, also known as a 
MTS assay, was used to test the proliferation of the T47D cells after being treated with the respective 
hormones during each test. The cells were plated in Falcon brand 96 well plates and allowed to grow to 
approximately 80% confluence. The media was replaced with 100 µl of phenol red free assay media and 
the different concentrations of hormones were achieved via serial dilution. The total amount of DMSO 
(1%) was maintained across all wells as to insure more accurate hormone responses. The plate was left for 
24 hours with the hormones. 20 µl of the Promega assay was added to each well and allowed to develop 
for 3 hours. After the three hours the plates were read at 450 nanometers with a BioTek EL800 plate 
reader. The plate design can be seen in Figure 4.  
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Figure 4: Proposed set up of the hormone test plates 
 
 In an effort to confirm the results obtained with the MTS assay, immunoblotting for Proliferating 
Cell Nuclear Antigen (PCNA) was also conducted. To prepare the cells for blotting, they had all media 
removed and were frozen at -80°C. All wells for each hormone concentration were then scraped into 
Lawmmli sample buffer and added to a 1.5ml Eppendorf tube. The tubes were then placed in a heating 
block to denature the proteins and then loaded into prepared gels. The gels were made of 3.9% and 12% 
acrylamide in the stacking and separating sections, respectively. With the voltage set at 120 mV, the gels 
were run for approximately 60 minutes in running buffer until the dye was near the bottom of the gel. The 
proteins were then transferred to a Millipore Immobilon P
TM
 membrane via semi-dry blotting technique. 
The blotting was run at 60 milliamps for 90 minutes. 5% non-fat dry milk in phosphate buffered saline 
(PBS) was used to block the membrane for about 30 minutes. The membrane was then incubated for 60 
minutes in a 1:750 dilution of PCNA primary antibody (from Santa Cruz Biotechnology) in blocking 
buffer, after which the membrane was washed three times with PBS. Goat anti-mouse antibody (from 
Santa Cruz Biotechnology) was then applied to the membrane in a 1:750 dilution in blocking buffer. 
Extra antibody was removed with three rinses of PBS. Developing the band was done via dissolving 1 
SigmaFAST BCIP
®
/NBT tablet in 10 ml of rdH2O and applying it to the membrane until the bands 
developed.  
 
Data Analysis 
All wells from a given concentration were converted to percent difference from the control and 
then averaged with other wells of the same hormone and concentration. Error was calculated as standard 
deviation of the mean. 
  
Results 
Assay Validation 
In order to assure that the MTS was functioning correctly, increasing cell concentrations were 
plated across a 96 well plate, as seen in Figure 5. The cells were allowed to establish themselves in the 
wells for 24 hours in the standard growth media. The media was replaced with phenol red free and cells 
were allowed to grow for another 24 hours, after which 20µl of the MTS assay was added to each well 
and allowed to develop for 3 hours. The plate was then read in the plate reader to provide the values seen 
in Figure 6.  Figure 7 shows the graphed values from the plate demonstrating a trend-based increase in the 
values thus showing that the assay was functioning as intended.  
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B 
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C 
 
5,000 5,000 10,000 10,000 15,000 15,000 20,000 20,000 25,000 25,000 
 
D 0,000 
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30,000 30,000 35,000 35,000 40,000 40,000 45,000 45,000 50,000 50,000 
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30,000 30,000 35,000 35,000 40,000 40,000 45,000 45,000 50,000 50,000 
 
H 
            
Figure 5: MTS Assay Validation Experimental Layout for a 96 Well Plate 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 0.039 0.039 0.039 0.04 0.039 0.039 0.04 0.043 0.039 0.041 0.04 0.04 
B 0.04 0.34 0.634 0.785 0.741 1.164 1.233 1.273 1.478 1.472 1.386 0.04 
C 0.039 0.489 0.511 0.615 0.838 1.182 1.098 1.357 1.41 1.388 1.417 0.041 
D 0.324 0.041 0.04 0.04 0.04 0.04 0.04 0.04 0.04 0.039 0.04 0.042 
E 0.312 0.041 0.04 0.042 0.042 0.041 0.042 0.041 0.038 0.041 0.04 0.041 
F 0.04 1.654 1.703 1.698 1.604 1.853 1.782 1.792 2.253 1.696 1.355 0.039 
G 0.043 1.695 1.673 1.721 1.801 1.727 1.795 1.974 1.671 1.417 1.29 0.041 
H 0.04 0.041 0.043 0.039 0.04 0.04 0.04 0.041 0.04 0.042 0.04 0.039 
Figure 6: MTS Assay Validation Results 
 
 
Figure 7: Graph of MTS One-Step Cell Proliferation Assay Validation 
Estrogen Responsiveness 
The T47D cell line was tested for estrogen responsiveness. This test was done with 17-Estradiol 
dissolved in either ethanol or DMSO as a means of concluding which solvent was most appropriate for 
the cell line.  
DMSO   
 As seen in Figure 8, 10µl and 1µl of DMSO were tested on the cells. 17-estradiol concentrations 
from 0µM to 100µM were tested in both volumes of DMSO.  
 
10µL of DMSO Stock Solution per Well 1µL of DMSO Stock Solution per Well 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
No Cells 
 
    
No Cells 
 
   
B 
 
100µM 10µM 1µM 0.1µM 0.01µM 
 
100µM 10µM 1µM 0.1µM 0.01µM 
C 
 
100µM 10µM 1µM 0.1µM 0.01µM 
 
100µM 10µM 1µM 0.1µM 0.01µM 
D 0µM 100µM 10µM 1µM 0.1µM 0.01µM 0 µM 100µM 10µM 1µM 0.1µM 0.01µM 
E 0µM 100µM 10µM 1µM 0.1µM 0.01µM 0 µM 100µM 10µM 1µM 0.1µM 0.01µM 
F 0µM 100µM 10µM 1µM 0.1µM 0.01µM 0 µM 100µM 10µM 1µM 0.1µM 0.01µM 
G 0µM 100µM 10µM 1µM 0.1µM 0.01µM 0 µM 100µM 10µM 1µM 0.1µM 0.01µM 
H 0µM 100µM 10µM 1µM 0.1µM 0.01µM 0 µM 100µM 10µM 1µM 0.1µM 0.01µM 
Figure 8: Experimental Design for Estrogen Responsiveness using DMSO 
 Figure 9 shows the spectrophotometer results for each well in the testing plate outlined in Figure 
8.  It can be seen that the empty wells gave very similar readings, meaning the spectrophotometer 
performed correctly.   
 
 
10µL of DMSO Stock Solution per Well 1µL of DMSO Stock Solution per Well 
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 0.04 0.323 0.326 0.327 0.329 0.33 0.047 0.326 0.318 0.323 0.309 0.291 
B 0.04 0.405 0.455 0.492 0.569 0.508 0.043 0.555 0.69 0.619 0.488 0.561 
C 0.04 0.38 0.486 0.514 0.531 0.501 0.041 0.54 1.296 0.636 0.722 0.74 
D 0.372 0.38 0.523 0.683 0.633 0.537 0.682 0.605 0.745 0.838 0.993 0.658 
E 0.524 0.473 0.591 0.694 0.547 0.589 1.078 0.594 0.824 0.958 0.814 1.343 
F 0.554 0.457 0.505 0.591 0.594 0.55 0.735 0.5 0.751 1.038 0.842 0.876 
G 0.453 0.46 0.586 0.474 0.501 0.676 0.732 0.609 0.747 0.829 0.879 0.957 
H 0.359 0.446 0.582 0.617 0.599 0.535 0.799 0.6 0.805 0.753 0.842 0.643 
Figure 9: Experimental Results for Estrogen Responsiveness Using DMSO 
 
 The spectrophotometer readings in Figure 9 were graphed to create Figure 10 showing the 
difference between using 10µL of DMSO and 1µL of DMSO in testing the phytoestrogen concentrations. 
Higher spectrophotometer results were produced using 1uL of DMSO, indicating it as a more viable 
option as the testing volume. However, estrogen responsiveness was seen at the lowest concentrations of 
estrogen. 
 
Figure 10: Graph of Results for Estrogen Responsiveness Test Using DMSO 
Ethanol 
 As seen in Figure 11, 10µl and 1µl of ethanol were tested on the cells. 17- Estradiol levels from 
only 0µM to 10µM were tested in both volumes of ethanol due to stock concentration.  
 
10µL of Ethanol Stock Solution per Well 
 
1µL of Ethanol Stock Solution per Well 
  
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
No Cells 
 
   
No Cells 
 
  
B 
 
10µM 1µM 0.1µM 0.01µM 
  
1µM 0.1µM 0.01µM            
 
C 
 
10µM 1µM 0.1µM 0.01µM 
  
1µM 0.1µM 0.01µM 
  
D 
 
10µM 1µM 0.1µM 0.01µM 
  
1µM 0.1µM 0.01µM 
  
E 0µM 10µM 1µM 0.1µM 0.01µM 
  
1µM 0.1µM 0.01µM 
  
F 0µM 10µM 1µM 0.1µM 0.01µM 
 
0µM 1µM 0.1µM 0.01µM 
  
G 0µM 10µM 1µM 0.1µM 0.01µM 
 
0µM 1µM 0.1µM 0.01µM 
  
H 0µM 10µM 1µM 0.1µM 0.01µM 
 
0µM 1µM 0.1µM 0.01µM 
  
Figure 11: Experimental Design for Estrogen Responsiveness Using Ethanol 
 
Figure 12 shows the spectrophotometer results for each well in the testing plate outlined in Figure 
8.  It can be seen that the empty wells gave very similar readings, indicating the spectrophotometry was 
performed correctly.   
 
 
10µL of Ethanol Stock Solution per Well 
 
1µL of Ethanol Stock Solution per Well 
  
 
1 2 3 4 5 6 7 8 9 10 11 12 
A 0.042 0.368 0.325 0.32 0.318 0.04 0.04 0.303 0.309 0.304 0.04 0.041 
B 0.046 0.363 0.371 0.401 0.386 0.051 0.041 0.584 0.474 0.611 0.046 0.039 
C 0.044 0.352 0.388 0.429 0.402 0.049 0.045 0.59 0.498 0.474 0.038 0.038 
D 0.043 0.374 0.372 0.371 0.388 0.044 0.055 0.77 0.639 0.435 0.041 0.043 
E 0.394 0.356 0.372 0.376 0.397 0.042 0.049 0.678 0.685 0.896 0.044 0.044 
F 0.426 0.37 0.365 0.413 0.469 0.05 0.846 0.738 0.688 0.638 0.04 0.047 
G 0.384 0.358 0.388 0.401 0.488 0.046 0.69 1.145 0.976 0.931 0.045 0.047 
H 0.539 0.419 0.469 0.517 0.56 0.044 0.749 0.749 0.421 0.687 0.039 0.041 
Figure 12: Experimental Results for Estrogen Responsiveness Using Ethanol 
 
The spectrophotometer readings in Figure 12 were graphed to create Figure 13; showing the 
difference between using 10µL or 1µL of ethanol in testing the phytoestrogen concentrations. Higher 
spectrophotometer results were produced using 1uL of ethanol as compared to 10µL. The cells did not 
appear to be estrogen responsive at any concentration.  
 
 
 
Figure 13: Graph of Results for Estrogen Responsiveness Test Using Ethanol 
Phytoestrogen Testing 
 Biochanin A and formononetin were tested on T47D cells in 96 well plates in concentrations 
ranging from 0µM to 100µM. Biochanin was tested on two plates and formononetin was tested on three 
to provide a broad enough base to provide reliable conclusions from the data.  
 Biochanin A 
 Figure 14 shows the plate design for the biochanin A plates. Hormone levels of 0µM to 100µM 
were tested. The values achieved, seen in Figures 15 and 16, were complied to create the graph seen in 
Figure 17. Figure 15 shows the values for the first biochanin A hormone test. Some inconsistencies were 
observed in the blank wells seen in columns 1 and 12. Possible inconsistencies were also found in the test 
wells in the remaining columns. Figure 16 shows the values for the second biochanin A hormone test. 
Much more consistent values were achieved in the blank wells of columns 1 and 12 as compared to 
Figure 15. In Figure 17 proliferation was seen at the concentrations of 10µM and lower, as compared to 
the decrease in cell number of those treated with 100µM of biochanin A.  
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
No Cells 
       
 
 
B 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.01µM 0.01µM 
 
C 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.01µM 0.01µM 
 
D 
 
100µM 100µM 10µM 10µM 1.0µM 1.0.µM 0.10µM 0.10µM 0.01µM 0.01µM 
 
E 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.01µM 0.01µM 
 
F 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.01µM 0.01µM 
 
G 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.01µM 0.01µM 
 
H 
 
0µM 0µM 0µM 0µM 0µM 0µM 0µM 0µM 0µM 0µM 
 
Figure 14: Experimental design for testing of Biochanin A 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0.04 0.069 0.09 0.32 0.337 0.334 0.323 0.345 0.331 0.365 0.315 0.039 
B 0.057 0.929 0.592 1.501 0.652 0.926 0.724 1.084 0.434 0.378 0.403 0.057 
C 0.075 1.067 1.223 1.597 1.323 1.518 1.454 0.643 1.022 0.571 1.332 0.07 
D 0.06 1.035 0.685 1.688 1.283 1.569 1.192 1.671 1.755 1.01 1.388 0.089 
E 0.049 0.808 0.904 1.259 1.395 1.187 1.285 1.469 1.527 1.663 1.255 0.074 
F 0.071 1.324 1.211 1.348 1.491 1.127 1.613 1.377 1.59 1.36 1.721 0.05 
G 0.053 0.992 0.985 1.402 1.591 1.52 1.716 1.346 1.429 1.74 1.434 0.076 
H 0.075 1.299 0.54 1.6 1.346 1.434 1.518 1.257 1.582 0.345 1.36 0.068 
Figure 15: Test plate 1 for the Biochanin A 
 
 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0.04 0.333 0.344 0.336 0.34 0.332 0.339 0.333 0.338 0.339 0.333 0.04 
B 0.039 0.609 0.624 1.217 1.366 1.102 1.139 1.347 1.16 0.992 1.033 0.04 
C 0.044 0.614 0.634 1.392 1.263 1.253 1.053 1.471 1.089 1.092 1.011 0.042 
D 0.045 0.606 0.651 1.292 1.368 1.204 1.238 1.291 1.218 1.073 1.122 0.06 
E 0.042 0.632 0.655 1.056 0.951 1.228 1.665 1.416 1.072 1.292 1.097 0.049 
F 0.043 0.641 0.659 1.304 1.167 1.176 1.151 1.157 1.025 1.125 1.034 0.065 
G 0.046 0.662 0.722 1.143 1.247 1.162 1.121 1.013 1.248 1.468 1.304 0.045 
H 0.085 0.842 0.785 0.785 0.795 0.797 0.963 1.096 1.111 1.477 1.233 0.082 
Figure 16: Test plate 2 for the Biochanin A 
 
 
Figure 17: Graphed spectrophotometer readings for Biochanin A plates graphed as percent difference from the control 
 
Formononetin 
 Figure 18 shows the plate design for the formononetin plates. Hormone levels of 0µM to 100µM 
were tested. The values achieved, seen in Figures 19 through 21, were used to create the graph seen in 
Figure 22.  
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 
 
No  Cells 
 
        
B 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.0100µM 0.01µM 
 
C 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.0100µM 0.01µM 
 
D 
 
100µM 100µM 10µM 10µM 1.0µM 1.0.µM 0.10µM 0.10µM 0.0100µM 0.01µM 
 
E 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.0100µM 0.01µM 
 
F 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.0100µM 0.01µM 
 
G 
 
100µM 100µM 10µM 10µM 1.0µM 1.0µM 0.10µM 0.10µM 0.0100µM 0.01µM 
 
H 
 
0µM 0µM 0µM 0µM 0µM 0µM 0µM 0µM 0µM 0µM 
 
Figure 18: Experimental design for testing of Formononetin 
 
Figure 19 shows the first values for the formononetin hormone test. Consistent values achieved in 
the blank wells of columns 1 and 12 indicate a properly run assay. 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0.04 0.36 0.611 0.342 0.348 0.348 0.322 0.355 0.333 0.34 0.326 0.04 
B 0.056 1.263 0.982 1.21 0.542 0.394 0.395 0.422 0.401 0.4 0.528 0.046 
C 0.06 1.217 1.458 1.527 0.436 0.404 0.385 0.348 0.4 0.378 0.396 0.05 
D 0.052 1.282 1.389 1.492 1.196 0.881 0.684 0.381 0.398 0.395 0.389 0.05 
E 0.069 1.243 1.442 1.66 1.544 1.706 1.715 0.422 0.434 0.573 0.458 0.05 
F 0.056 1.159 1.525 1.778 1.676 1.609 1.599 0.617 0.41 1.213 1.397 0.06 
G 0.052 1.672 1.359 1.572 1.788 1.738 1.684 1.309 0.83 1.506 1.249 0.065 
H 0.051 0.411 0.431 0.374 0.406 0.407 0.37 0.411 0.416 0.483 0.422 0.055 
Figure 19: Test plate 1 for Formononetin 
 
Figure 20 shows the second values for the formononetin hormone test. Consistent values achieved 
in the blank wells of columns 1 and 12 indicate properly run assay. 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0.04 0.364 0.359 0.358 0.351 0.356 0.354 0.364 0.357 0.356 0.355 0.04 
B 0.048 0.939 0.909 0.978 1.12 1.244 1.318 0.821 1.272 1.797 0.872 0.041 
C 0.053 0.941 1.018 1.115 1.022 0.974 0.907 0.923 1.245 0.87 1.052 0.042 
D 0.045 0.989 1.118 1.199 1.101 1.033 1.364 1.304 1.018 1.393 0.958 0.038 
E 0.056 1.073 1.076 1.219 1.102 1.157 0.998 1.156 0.88 1.012 1.119 0.04 
F 0.041 1.025 1.172 1.176 1.125 1.083 1.145 1.357 0.958 1.007 1.137 0.047 
G 0.043 0.998 1.127 1.125 1.118 1.136 1.082 1.293 0.86 0.922 1.163 0.044 
H 1.048 1.053 1.042 1.049 1.098 1.218 1.117 1.207 1.77 0.932 0.947 1.116 
Figure 20: Test plate 2 for Formononetin 
 
Figure 21 shows the third values for the formononetin hormone test. Some inconsistencies were 
observed in the blank wells seen in columns 1 and 12. Possible inconsistencies also found in the test wells 
in the remaining columns.  
 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0.035 0.345 0.357 0.343 0.057 0.057 0.059 0.056 0.058 0.057 0.057 0.035 
B 0.042 0.92 0.966 0.998 0.994 0.814 1.094 1.042 1.103 1.212 0.992 0.039 
C 0.041 0.996 1.155 1.038 1.217 1.207 1.302 1.007 1.221 0.967 1.289 0.04 
D 0.047 0.943 0.915 1.076 1.148 1.048 1.024 1.175 1.07 0.993 0.964 0.041 
E 0.047 0.765 0.743 1.037 0.851 0.948 0.918 0.914 0.842 0.849 0.893 0.048 
F 0.044 0.744 0.748 0.825 1.013 0.946 0.923 0.973 0.884 0.784 0.861 0.045 
G 0.052 1.17 0.733 0.692 0.787 0.832 0.816 0.711 0.901 0.796 0.851 0.048 
H 0.055 0.71 0.686 0.71 0.647 0.689 0.647 0.398 0.791 0.774 0.21 0.046 
Figure 21: Test plate 3 for Formononetin 
 
 Figure 22 shows the compiled and graphed data of the formononetin plates. No discernable 
pattern is evident in the cells response to the hormone stimulus.  
 
 
Figure 22: Graphed spectrophotometer readings for Formononetin plates graphed as percent difference from the control 
Immunoblotting for PCNA 
 In an effort to validate the results collected via MTS assays, immunoblotting for PCNA was 
conducted. Dark bands were observed, as seen in Figure 23. Analysis of the bands was done based on 
color intensity with the ImageJ computer program, as seen in Figures 24 and 25. Further analysis of the 
formononetin bands could not be done due errors with the gel.  
 
Figure 23: Immunoblot of PCNA of Biochanin A and Formononetin treated cells 
 
Concentration 
(µM) 
Area  Sampled 
(Pixels) 
Sample 1 Sample 2 Sample 3 Average 
Standard 
Deviation of the 
Mean 
0 16640 111.121 111.151 110.842 111.038 0.098382 
0.01 16640 96.238 97.827 97.534 97.19967 0.488216 
0.1 16640 93.199 93.437 93.674 93.43667 0.137121 
1 16640 84.614 84.475 84.129 84.406 0.144195 
10 16640 82.7 83.494 82.353 82.849 0.337699 
100 16640 92.346 92.508 93.604 92.81933 0.395111 
Figure 24: Values collected via ImageJ for Biochanin A PCNA bands 
 Figure 25: Graphed mean gray value assessed by ImageJ showing different intensities of bands achieved via 
immunoblotting for PCNA 
 Densitometry values suggest that there may be a slight inhibitory effect of biochanin A on PCNA 
expression at all concentrations tested. This is not consistent with the trends seen for cell proliferation; 
however the immunoblotting was only done once, thus limiting any significant interpretation of the 
results.  
  
  
Discussion 
 The goal of this project was to determine if the phytoestrogens biochanin A and formononetin 
had proliferative effects on the T47D human ductal carcinoma cell line.  Based on a thorough literature 
review, it was hypothesized that both of the tested phytoestrogens would cause proliferation at 
concentrations less than 10µM, and inhibit at higher concentrations such as 100µM. 
 This project was a continuation of previous phytoestrogen projects completed at WPI.  A review 
of methodologies from these projects prompted the examination of each part of the experimental design: 
cell line estrogen responsiveness, proliferation assay, hormone solvent, and hormone concentrations were 
all verified.  The T47D cell line was chosen because the MCF7 cell line owned by WPI had been shown 
unresponsive to estrogen (30).   
The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS) was chosen 
because it was not radioactive like other assays, simple to use, and readily repeatable.  A stock of assay 
was available from previous experiments, and needed to be validated prior to experimentation.  On the 
principal that the MTS assay relates the relative amount of viable cells in a population, it can be validated 
by application to increasing cell concentrations.  Figure 7 displays the relative linearity in absorbance 
readings, following increasing cell concentration.  This plate also served as a test for optimal cell seeding 
density.  Wells were inspected for confluence at the assay time point, and it was determined that a seeding 
density of 20,000 cells per well was sufficient as it would allow for a range of readings within the linear 
range of the assay as cell density changed with hormone treatment.    
In creating the experimental design for this project, an appropriate hormone solvent was 
investigated.  Both DMSO and ethanol were utilized equally in the literature, and both are cytotoxic.  
Also, the Promega protocol for the MTS assay states that strong reducing substances like DMSO can 
reduce tetrazolium salts nonenzymatically and lead to increased background absorbance values.  Because 
of these concerns, an experiment was conducted to determine the optimal solvent, and concentration of 
that solvent that T47D cells could tolerate without affecting the MTS assay.   
In an effort to maximize results from this experiment, estrogen responsiveness of the T47D cell 
line was also tested.  A preparation of 100µM estrogen in ethanol was already available from a concurrent 
MQP project, and a stock solution of 10,000 µM of estrogen in DMSO was created.  It was found that 
ethanol at 10µL per well or 10% of final volume, was cytotoxic and produced very low 
spectrophotometric readings.  Also, 1µL of ethanol produced highly variable results, and no estrogen 
responsiveness was observed in either case.  Figure 13 shows the negative results of the estrogen-ethanol 
test.   In contrast, estrogen responsiveness was demonstrated with DMSO at both 1% and 10% total 
volume.  Figure 10 illustrates how the T47D cells increased proliferation from 0.01µM to approximately 
10µM.  These results also confirmed that DMSO did not act as a significant reducing agent.  If DMSO 
was effectively reducing the tetrazolium compound in the MTS assay, the wells with 10% DMSO would 
be expected to show higher readings than those wells with 1% DMSO.  This was not the case as 1% 
DMSO produced higher readings.  DMSO was chosen as the hormone solvent for this project because it 
was the least toxic to cells at a concentration of 1%.   
 In order to determine the proliferative effects of biochanin A and formononetin, the MTS assay 
and a PCNA assay were utilized.  Figure 17 shows the averaged effects of both MTS assays for the effects 
of biochanin A.  Biochanin A increased T47D cell proliferation at concentrations between 0.01µM and 
10µM.  This proliferative effect was significantly greater in the 10µM concentration than the 0.01µM 
populations, and cannot be accounted for by standard deviation of the mean.  At 100µM however, 
proliferation decreased greatly from the control.   
 The same test was conducted with formononetin, and repeated three times.  The first plate, shown 
in Figure 19 had significant errors.  Many wells in each concentration failed to develop, including wells in 
the control lane.  A reasonable explanation for this error was not found, so the plate was excluded from 
analysis.  The second plate developed as expected, and results are shown in Figure 20.  
Error also occurred with the third plate.  During the change to clear media, the control wells were 
left without media for approximately fifteen minutes in the incubator.  This resulted in greatly decreased 
readings in the control from all other wells.  Because of this laboratory error, it was impossible to have an 
accurate control for that plate, and it was excluded.  However, the results for the hormone concentrations 
in this plate mirrored those results found in the second plate.  Overall, both plates showed no increased or 
decreased proliferation between all formononetin concentrations and the control.   
Though many studies support the idea that formononetin causes proliferation (28) (29) (25), 
others have found results similar to the ones presented here.  In a large study of phytoestrogens, one of the 
only phytoestrogen that could not induce MCF7 cell proliferation was formononetin.  The authors 
actually suggested that formononetin was toxic to the cells at the tested concentrations.  They also found 
that biochanin A increased estrogen responsive MCF7 cell proliferation at concentrations less than 10µM, 
but inhibited at  concentrations greater than 25µM (31). These results mirror those found in this study. 
Another interesting study which used very similar assay methodology to this project also found 
comparative results.  T47D and MCF7 cells were exposed to concentrations of biochanin A and 
formononetin ranging from 0.01µM to 10µM in 1% DMSO.  They were assayed for proliferation using 
Alamar Blue, and estrogenic activity using a luciferase reporter construct. In the MCF7 cell line, the 
scientists found no concentration of formononetin under 100µM could stimulate proliferation.  Biochanin 
A, however, caused the same proliferative effects as 10 or 100µM of estradiol at 0.2µM and 0.3µM 
respectively.  This shows that in MCF7 cells, formononetin has no proliferative effect, but biochanin has 
very high proliferative capabilities (32).  These results are also similar to the ones presented above. 
Umehara et al repeated the same testing with the T47D cell line.   Formononetin was found to 
have some proliferative effects: only 0.03 µM was needed to produce the same results as 10µM estradiol. 
 However, no amount of formononetin could still produce effects similar to 100uM estradiol (32).  This 
change in the effects of low levels of formononetin seemingly conflicts with their MCF7 results. 
 However, these results can be explained by the differences in the two cell lines.  MCF7 cells have 
become notorious recently as a line that has become highly variable due to laboratory selection.    If we 
assume that the T47D cell line used by Umehara has retained estrogen responsiveness, and the MCF7 line 
has become unresponsive, it would point to biochanin A working through an estrogen receptor 
independent pathway, and formononetin working through the estrogen receptor. 
 Despite the consistent and repeatable results garnered from the MTS assay, PCNA data 
contradicted the original findings.  The immunoblot showed, with little analytical error, that biochanin A 
inhibited PCNA expression in a dose dependent manner from 0.01 µM to 10 µM, and then showed 
slightly elevated but still inhibitory effects at 100µM.    This shows an almost inverse relationship to the 
MTS data.  PNCA has been used consistently to classify various types of breast cancer in vivo with great 
accuracy for poor prognostic cases (33) (34).  It is a well known and trusted mode of assaying for cell 
proliferation.  However, authors have found that that in certain breast cancers, the relationship between 
PCNA expression and cell proliferation is lost, but is increased in tissues adjacent to tumors (35). This 
could be a possible explanation for the discrepancy between the MTS assay and PCNA assay results. 
More testing would be needed to verify this.   
 The formononetin PCNA immunoblot had significant errors such that it could not be analyzed.  
The wells did not form correctly, and so samples ran together before voltage was applied.  Also, air 
bubbles were trapped in the gel and distorted two of the possible bands.  It is proposed that both of these 
gels should be interpreted with caution as protein normalization through laboratory means could not be 
undertaken as all samples were combined with sample buffer immediately post-aspiration of media. 
 For subsequent projects, it is suggested that concentrations of phytoestrogens between 10µM and 
100uM be tested in addition to the ones used in this study.  For biochanin A, this would help determine 
the exact concentration at which proliferation becomes inhibited.  It is also suggested that a normal breast 
biopsy, possibly from a reduction surgery, should be used as a control for normal cells.  These would not 
be identical to the cancer cells, but would serve as a control, allowing researchers to determine the effects 
of phytoestrogens not only on cancer cells, but also on healthy breast tissue.  The final suggestion is a 
replication of the PCNA immunoblot as only one out of four gels developed for each hormone tested.   
 In conclusion, Biochanin A induces T47D cell proliferation from concentrations of 0.01µM to 
10µM, and inhibits at 100µM.  Formononetin has no affect on proliferation at any of the tested 
concentrations.   If these results are statistically significant, they have important implications for over the 
counter hormone replacement therapies.  They indicate that the effects of certain phytoestrogens can be 
dose dependent, or devoid of estrogenic activity.  Because there is little consistency between products and 
even lot numbers of the same product, women may be receiving different concentrations than the product 
labeling indicates.  Also, if one hormone is more estrogenic than the other, the same variability will result. 
So, despite their "natural" label, women should be skeptical and discerning when it comes to over the 
counter phytoestrogen therapies. 
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